Goal: To identify anemia management practices for safely and effectively achieving appropriate hemoglobin (Hb) targets, reducing ESA requirements, addressing elevated serum ferritin levels, and overcoming obstacles to effective erythropoiesis.
Evaluate a case study involving an increase in maintenance IV iron to improve Hb levels and overall patient outcomes.
Understand how to interpret updated KDOQI and FDA recommendations that address emerging information about ESAs, Hb targets, IV iron, and patients with elevated serum ferritin levels.
Discuss the relevance of this information for treating patients on hemodialysis who have anemia and recent evidence that IV iron administration is an effective solution for such patients.
Note: The author has disclosed that she is on Watson Pharma's Speaker Bureau.
Note: This article is supported by a financial grant from Watson Pharma, Inc. This article has undergone peer review. The information in this article does not necessarily reflect the opinions of ANNA or the sponsor.